Johnson & Johnson (JNJ) Total Non-Current Liabilities (2009 - 2026)

Johnson & Johnson (JNJ) posted Total Non-Current Liabilities of $119.2 billion for Q1 2026, up 1.74% sequentially from $117.2 billion in Q4 2025, and up 4.28% YoY from $114.3 billion in Q1 2025.

Johnson & Johnson (JNJ) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends

Johnson & Johnson (JNJ) has 18 years of Total Non-Current Liabilities data on file, last reported at $119.2 billion in Q1 2026.

  • Quarterly Total Non-Current Liabilities rose 4.28% year-over-year to $119.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $119.2 billion (up 4.28% YoY) and the FY2025 annual result came in at $117.2 billion, up 9.11% from the prior year.
  • Total Non-Current Liabilities rose to $119.2 billion in Q1 2026 per JNJ's latest filing, from $117.2 billion in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $124.0 billion in Q2 2023, with the low at $93.7 billion in Q4 2023.
  • Average Total Non-Current Liabilities over 5 years is $107.4 billion, with a median of $107.2 billion recorded in 2024.
  • Year-over-year, Total Non-Current Liabilities climbed 20.16% in 2023 and fell 18.66% in 2024.
  • Johnson & Johnson's Total Non-Current Liabilities stood at $100.0 billion in 2022, then dropped by 2.31% to $97.7 billion in 2023, then gained by 9.93% to $107.4 billion in 2024, then increased by 9.11% to $117.2 billion in 2025, then increased by 1.74% to $119.2 billion in 2026.
  • Business Quant data shows JNJ's Total Non-Current Liabilities at $119.2 billion in Q1 2026, $117.2 billion in Q4 2025, and $103.6 billion in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 48.74 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 119.22 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 109.01 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn -34.06 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn 75.17 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 80.55 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 31.56 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 113.51 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn - 100.00 Mn
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn 10.04 Bn

Historic Data

Download Data
DateValue
Mar 29, 2026 119.22 Bn
Dec 28, 2025 117.18 Bn
Sep 28, 2025 103.61 Bn
Jun 29, 2025 104.65 Bn
Mar 30, 2025 114.33 Bn
Dec 29, 2024 107.40 Bn
Sep 29, 2024 106.91 Bn
Jun 30, 2024 108.30 Bn
Mar 31, 2024 100.83 Bn
Dec 31, 2023 97.69 Bn
Oct 1, 2023 93.66 Bn
Jul 2, 2023 114.14 Bn
Apr 2, 2023 123.96 Bn
Jan 1, 2023 109.45 Bn
Oct 2, 2022 100.00 Bn
Jul 3, 2022 100.83 Bn
Apr 3, 2022 103.16 Bn
Jan 2, 2022 107.46 Bn
Oct 3, 2021 108.34 Bn
Jul 4, 2021 106.27 Bn